This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

ICON3 trial

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The ICON3 trial compared the efficacy of:

  • an experimental treatment of carboplatin and paclitaxel, with
  • control treatment of either single agent carboplatin or CAP (cyclophosphamide, cisplatin and doxorubicin)

2074 patients with ovarian carcinoma were randomised to experimental treatment or control. The type of control treatment was decided upon by clinician and patient before randomisation. The primary endpoint was overall survival. Analysis was by intention to treat.

Reference:

The International Collaborative Ovarian Neoplasm (ICON) Group (2002). Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002; 360: 505-15

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.